StockData

Lyell Immunopharma vs Virax Biolabs

LYEL and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LYEL and VRAX compare

Virax Biolabs grew revenue faster over the last twelve months (96.2% versus −55.0% for Lyell Immunopharma).

Virax Biolabs keeps more of each dollar of sales as profit, with a net margin of −40439% compared with −920285% at Lyell Immunopharma.

Virax Biolabs scores higher on the StockData Score (9 against 6 for Lyell Immunopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLYELVRAX
Size and price
Market cap$335M–
Share price$13.67$0.445
Change, 1 year−19.3%−96.4%
Change, 5 years−92.7%–
Beta (5Y)1.373.55
StockData Score
Total score69 (better)
Valuation score1 (better)0
Growth score03 (better)
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S12407×–
P/B1.4×–
FCF yield−40.0%–
Growth
Revenue growth (TTM)−55.0%96.2% (better)
Revenue growth, 5Y average−65.9%−36.9% (better)
Profitability
Gross margin–61.9%
Operating margin−949981%−51515% (better)
Net margin−920285%−40439% (better)
FCF margin−496189%−39264% (better)
Return on equity−93.3%−75.7% (better)
Return on invested capital−782%−388% (better)
Financial health
Debt / equity0.000.00
Current ratio5.369.97 (better)
Altman Z-score−7.05–
Piotroski F-score26 (better)
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions48.9%0.00%
Held by insiders45.0%63.6%
Insider net buying, 12 months$74.4M–
Short interest, % of float10.5%3.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.